GOALS OF WORK: Data suggest that treatment with luteinizing hormone-releasing hormone (LHRH) agonists may be associated with reduced cognitive functioning. The purpose of the current study was to compare rates of clinically significant cognitive impairment in men treated with LHRH agonists to a matched sample of healthy men without cancer. MATERIALS AND METHODS: Participants were 48 men receiving LHRH agonist therapy for prostate cancer and 48 men with no history of cancer matched to patients on age and education. Participants were administered a battery of neuropsychological tests assessing the domains of verbal memory, verbal fluency, visuospatial memory, visuospatial abilities, and executive function. Clinically significant impairment on individual tests was defined as -1.5 SD below the normative mean; overall impairment was defined as impaired performance on two or more tests. MAIN RESULTS: Patients did not differ from comparison subjects in age, ethnicity, race, education, or annual household income (p's > 0.05). No statistically significant differences in test means were found. Nevertheless, patients displayed greater overall impairment in cognitive functioning than comparison subjects (42% of patients versus 19% of comparison subjects, p < 0.05). Among patients, prior prostatectomy was associated with impaired immediate and delayed verbal memory (p's < 0.05). CONCLUSIONS: Current findings suggest that LHRH agonists and surgery for prostate cancer are associated with clinically significant impairment in cognitive functioning. Longitudinal studies are needed to examine changes in cognitive impairment before and after surgical and hormonal treatment for prostate cancer. Patients undergoing LHRH agonist therapy should be monitored for cognitive changes while on treatment.
GOALS OF WORK: Data suggest that treatment with luteinizing hormone-releasing hormone (LHRH) agonists may be associated with reduced cognitive functioning. The purpose of the current study was to compare rates of clinically significant cognitive impairment in men treated with LHRH agonists to a matched sample of healthy men without cancer. MATERIALS AND METHODS:Participants were 48 men receiving LHRH agonist therapy for prostate cancer and 48 men with no history of cancer matched to patients on age and education. Participants were administered a battery of neuropsychological tests assessing the domains of verbal memory, verbal fluency, visuospatial memory, visuospatial abilities, and executive function. Clinically significant impairment on individual tests was defined as -1.5 SD below the normative mean; overall impairment was defined as impaired performance on two or more tests. MAIN RESULTS:Patients did not differ from comparison subjects in age, ethnicity, race, education, or annual household income (p's > 0.05). No statistically significant differences in test means were found. Nevertheless, patients displayed greater overall impairment in cognitive functioning than comparison subjects (42% of patients versus 19% of comparison subjects, p < 0.05). Among patients, prior prostatectomy was associated with impaired immediate and delayed verbal memory (p's < 0.05). CONCLUSIONS: Current findings suggest that LHRH agonists and surgery for prostate cancer are associated with clinically significant impairment in cognitive functioning. Longitudinal studies are needed to examine changes in cognitive impairment before and after surgical and hormonal treatment for prostate cancer. Patients undergoing LHRH agonist therapy should be monitored for cognitive changes while on treatment.
Authors: Scott D Moffat; Alan B Zonderman; E Jeffrey Metter; Marc R Blackman; S Mitchell Harman; Susan M Resnick Journal: J Clin Endocrinol Metab Date: 2002-11 Impact factor: 5.958
Authors: Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: H J Green; K I Pakenham; B C Headley; J Yaxley; D L Nicol; P N Mactaggart; C Swanson; R B Watson; R A Gardiner Journal: BJU Int Date: 2002-09 Impact factor: 5.588
Authors: H J Green; K I Pakenham; B C Headley; J Yaxley; D L Nicol; P N Mactaggart; C E Swanson; R B Watson; R A Gardiner Journal: BJU Int Date: 2004-05 Impact factor: 5.588
Authors: Heather L McGinty; Kristin M Phillips; Heather S L Jim; Julie M Cessna; Yasmin Asvat; Mallory G Cases; Brent J Small; Paul B Jacobsen Journal: Support Care Cancer Date: 2014-05-25 Impact factor: 3.603
Authors: Lisa M Wu; Michael A Diefenbach; Wayne A Gordon; Joshua B Cantor; Monique M Cherrier Journal: Urol Oncol Date: 2012-09-10 Impact factor: 3.498
Authors: Byeongsang Oh; Phyllis N Butow; Barbara A Mullan; Stephen J Clarke; Philip J Beale; Nick Pavlakis; Myeong Soo Lee; David S Rosenthal; Linda Larkey; Janette Vardy Journal: Support Care Cancer Date: 2011-06-19 Impact factor: 3.603
Authors: Brian D Gonzalez; Heather S L Jim; Margaret Booth-Jones; Brent J Small; Steven K Sutton; Hui-Yi Lin; Jong Y Park; Philippe E Spiess; Mayer N Fishman; Paul B Jacobsen Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: Natalie G Regier; Aanand D Naik; Elizabeth A Mulligan; Ziad S Nasreddine; Jane A Driver; Yvonne H-F Sada; Jennifer Moye Journal: Psychooncology Date: 2019-06-13 Impact factor: 3.894
Authors: Aasha I Hoogland; Heather S L Jim; Brian D Gonzalez; Brent J Small; Danielle Gilvary; Elizabeth C Breen; Julienne E Bower; Mayer Fishman; Babu Zachariah; Paul B Jacobsen Journal: Cancer Date: 2020-12-30 Impact factor: 6.860